Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Jade Biosciences Inc (JBIO)

118 + Investors. Track Smart Money conviction in JBIO. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +13
Streak
4Q ▲
Buyers last Q
58%

Smart Money Signals — JBIO

Based on 118 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added JBIO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
118 hedge funds hold JBIO right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +11700% more funds vs a year ago

fund count last 6Q
+117 new funds entered over the past year (+11700% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 58% buying

65 buying48 selling
Last quarter: 65 funds bought or added vs 48 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-9 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 68 → 9 → 36 → 27. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔄

Mostly new holders — 51% entered in last year

■ 3% conviction (2yr+) ■ 46% medium ■ 51% new
Only 4 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
📊

Peak discovery — momentum slowing

0 → 68 → 9 → 36 → 27 new funds/Q
New funds entering each quarter: 68 → 9 → 36 → 27. JBIO is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🌱

Early stage — 94% of holders entered in last year

■ 6% veterans ■ 0% 1-2yr ■ 94% new
Of 121 current holders: 114 (94%) entered in the past year, only 7 (6%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
✅

Strong quality — 26% AUM from major funds

26% from top-100 AUM funds
31 of 116 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
6.3
out of 10
Moderate Exit Risk
Exit risk score 6.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — JBIO

In 2026 Q1, 65 hedge funds were net buyers of JBIO (27 opened a new position, 38 added to an existing one), while 48 reduced or exited (34 trimmed, 14 sold completely) — a 58% buyer ratio, indicating a slight buying edge. This marks 4 consecutive quarters of net institutional buying — a persistent conviction signal. 26% of total institutional value in JBIO is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +13 funds (more new holders than closures). Total institutional holders: 118.

Hedge Fund Ownership: JBIO

How many hedge funds hold JBIO — quarterly history vs. share price
Quarterly hedge fund ownership of JBIO vs. share price

Market Analysis: JBIO

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: JBIO

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Jade Biosciences Inc (JBIO) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much JBIO has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 79d ago
JBIO
+10.5%
XLV
+2.1%

JBIO outperformed XLV by +8.4% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 34d ago
JBIO
-33.5%
XLV
+3.1%

Since the filing became public, JBIO outperformed XLV by -36.6% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

13 top-rated funds 5 high-conviction
Consensus
5.0
/ 10
breadth
×
Elite
4.6
/ 10
conviction
Hedge Fund Positioning: JBIO
118 + Investors

Track Smart Money conviction in JBIO. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 118 105 12.38%
13F Shares 50M 47M 5.76%
Total Value $715M $727M -1.73%
New Positions 27 36 -9
Increased Positions 39 42 -3
Closed Positions 14 5 +9
Reduced Positions 33 14 +19
Total Calls 1 0 100%
Total Puts 4 3 33.33%
PUT/CALL Ratio 4.0 0.0 Bearish

Statistics: JBIO

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

118 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in JBIO. Verified SEC 13F-HR filings.

QUARTER:
Top 25 JBIO holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Versant Venture Management, LLC 15.16% 1,525,820 $21.4M
2 Avidity Partners Management LP 7.73% 1,400,708 $34.2M
3 Remedium Capital Partners, LLC 6.93% 1,577,750 $22.2M
4 Fairmount Funds Management LLC 4.62% 4,553,494 $64.0M
5 Acorn Capital Advisors, LLC 3.14% 786,760 $11.1M
6 Great Point Partners LLC 3.11% 964,462 $13.6M
7 Venrock Adviser, LLC 1.69% 3,220,364 $45.2M
8 Samsara BioCapital, LLC 1.32% 968,798 $13.6M
9 Bellevue Group AG 1.17% 3,501,502 $49.2M
10 Foresite Capital Management VI LLC 0.98% 320,000 $4.5M
11 Opaleye Management Inc. 0.79% 427,608 $6.0M
12 Ikarian Capital, LLC 0.58% 512,349 $7.2M
13 Ra Capital Management, L.P. 0.55% 3,671,083 $51.6M
14 Affinity Asset Advisors, LLC 0.46% 639,956 $9.0M
15 Soleus Capital Management, L.P. 0.45% 796,744 $11.2M
16 Stempoint Capital LP 0.42% 154,034 $2.2M
17 Logos Global Management LP 0.28% 400,000 $5.6M
18 Baker BROS. Advisors LP 0.13% 1,641,137 $23.1M
19 Rtw Investments, LP 0.08% 573,205 $8.1M
20 Virtus Investment Advisers, LLC 0.07% 18,203 $256K
21 Driehaus Capital Management LLC 0.07% 635,498 $8.9M
22 Sofinnova Investments, Inc. 0.06% 107,391 $1.5M
23 Orbimed Advisors LLC 0.05% 185,011 $2.6M
24 Deltec Asset Management LLC 0.04% 15,756 $221K
25 Boothbay Fund Management, LLC 0.03% 139,968 $2.0M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Jade Biosciences Inc (JBIO)

What does the Smart Money Trend signal show for JBIO?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added JBIO than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for JBIO?

Slight buying edge — 58% buying: Last quarter: 65 funds bought or added vs 48 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for JBIO holders?

Strong quality — 26% AUM from major funds: 31 of 116 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held JBIO?

Mostly new holders — 51% entered in last year: Only 4 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Jade Biosciences Inc (JBIO) following the 2026 Q1 hedge fund 13F filings?

As of today, JBIO has moved -33.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.1% for the XLV sector ETF — an outperformance of -36.6%. Since the quarter end (March 31, 2026), JBIO has gained +10.5% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →